Press release
Glioma market is projected to reach USD 7.8 billion by 2034
Glioma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71635
Standard treatments - including surgery, radiation, and chemotherapy (temozolomide) - have improved outcomes only modestly. However, the past decade has seen a surge in immunotherapies, targeted therapies, tumor-treating fields, and biomarker-driven strategies, transforming the glioma treatment landscape. Growing investments in neuro-oncology and global clinical trial activity make the glioma market a high-potential segment of oncology.
Market Overview
The global glioma market was valued at USD 3.5 billion in 2024 and is projected to reach USD 7.8 billion by 2034, growing at a CAGR of 8.3% over the forecast period.
Key Highlights:
• Rising incidence of gliomas, particularly glioblastoma, globally.
• Expanding clinical adoption of tumor-treating fields (TTFs) and targeted therapies.
• Strong pipeline of immunotherapies, including checkpoint inhibitors and vaccines.
• Advances in digital diagnostics and imaging improving early detection.
• Challenges include poor prognosis, therapy resistance, and high treatment costs.
Leading Players include Novocure, Roche, Bristol Myers Squibb, Merck & Co., Pfizer, Novartis, Amgen, Eli Lilly, and AstraZeneca, all actively involved in glioma research and commercialization.
Segmentation Analysis
By Product
• Chemotherapy Agents (temozolomide, nitrosoureas, etc.)
• Targeted Therapies (EGFR inhibitors, VEGF inhibitors)
• Immunotherapies (checkpoint inhibitors, vaccines, CAR-T cell therapies)
• Tumor Treating Fields (TTF) Devices
• Supportive Care
By Platform
• Biologics
• Small Molecules
• Medical Devices
• Combination Therapies
By Technology
• Tumor Treating Fields (TTF) Technology
• Immuno-Oncology Platforms
• Biomarker-Based Diagnostics
• AI-Enabled Imaging & Digital Pathology
By End Use
• Hospitals & Neuro-Oncology Centers
• Ambulatory Care Clinics
• Research & Academic Institutes
• Home-Based Care (TTF devices, supportive care)
By Application
• Glioblastoma Multiforme (GBM)
• Astrocytomas
• Oligodendrogliomas
• Other Glioma Subtypes
Summary:
Glioblastoma remains the largest and most critical segment, accounting for the majority of the glioma market. TTF devices and immunotherapies are expected to record the fastest growth through 2034, as innovation reshapes treatment standards.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71635/glioma-market
Regional Analysis
North America
• Largest market share, driven by strong clinical adoption of advanced therapies and active research networks.
• U.S. leads in FDA approvals and integration of TTF devices in glioblastoma care.
Europe
• Strong presence in neuro-oncology research and adoption of targeted therapies.
• Germany, France, and the UK are key contributors with robust healthcare systems.
Asia-Pacific
• Fastest-growing regional market due to rising incidence, expanding healthcare infrastructure, and growing clinical trial participation.
• China, Japan, and India are central to growth, with increasing government investments in oncology.
Middle East & Africa
• Smaller but developing market, with oncology modernization efforts expanding access to advanced therapies.
Latin America
• Moderate growth led by Brazil and Mexico.
• Rising healthcare investment and adoption of global oncology standards.
Summary:
While North America and Europe dominate, Asia-Pacific is projected to record the highest CAGR between 2024 and 2034, supported by large patient pools, clinical trial activity, and rising access to innovative therapies.
Market Dynamics
Growth Drivers
• Increasing incidence of gliomas globally.
• Expanding adoption of TTF devices and targeted therapies.
• Growing pipeline of immunotherapies and vaccines.
• Advances in diagnostics and imaging for early detection.
Challenges
• Limited survival improvements for aggressive gliomas.
• Blood-brain barrier complicating effective drug delivery.
• High treatment costs restricting global access.
Latest Trends
• Development of personalized medicine approaches based on genetic profiling.
• Expansion of CAR-T cell therapies and glioma vaccines.
• Integration of AI in neuroimaging and digital pathology for diagnosis.
• Growth of biosimilars to improve affordability.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71635
Competitive Landscape
Key Market Players:
• Novocure Ltd. (Optune - tumor treating fields device)
• Roche Holding AG
• Bristol Myers Squibb
• Merck & Co. (Keytruda - checkpoint inhibitor)
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Takeda Pharmaceuticals
Competition is shaped by pipeline development, regulatory approvals, and partnerships. Novocure dominates with TTF devices, while Roche, Merck, and BMS lead immunotherapy innovation. Collaboration with research institutes is accelerating clinical trial enrollment for novel therapies.
Conclusion
The glioma market is undergoing a significant transformation, driven by immunotherapies, TTF devices, and precision medicine approaches. With the global market projected to grow at a CAGR of 8.3% from 2024 to 2034, opportunities are abundant for pharma innovators, device manufacturers, and diagnostic providers.
Key opportunities include:
• Expansion of tumor treating fields (TTF) adoption across global oncology centers.
• Development of checkpoint inhibitors and glioma vaccines.
• Integration of AI-enabled imaging and biomarker diagnostics.
• Strongest growth potential in Asia-Pacific, where rising incidence and healthcare investment are fueling adoption.
As therapeutic innovation converges with digital diagnostics, the glioma market is expected to expand steadily, offering new hope for patients while creating strong opportunities for stakeholders worldwide.
This report is also available in the following languages : Japanese (神経膠腫市場), Korean (신경교종 시장), Chinese (胶质瘤市场), French (Marché du gliome), German (Gliommarkt), and Italian (Mercato del glioma), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71635/glioma-market#request-a-sample
Our More Reports:
Subarachnoid Hemorrhage Market
https://exactitudeconsultancy.com/reports/72076/subarachnoid-hemorrhage-market
Tardive Dyskinesia Market
https://exactitudeconsultancy.com/reports/72077/tardive-dyskinesia-market
Transient Ischemic Attack Market
https://exactitudeconsultancy.com/reports/72078/transient-ischemic-attack-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma market is projected to reach USD 7.8 billion by 2034 here
News-ID: 4173829 • Views: …
More Releases from Exactitude Consultancy
Uncomplicated Urinary Tract Infections (UTIs) Patient Pool Analysis Market Set t …
Introduction
Urinary tract infections (UTIs) are among the most common bacterial infections globally, affecting millions each year. Uncomplicated UTIs primarily occur in otherwise healthy individuals, most frequently women, and are caused by pathogens such as Escherichia coli. These infections, while not life-threatening, impose a significant healthcare and economic burden due to high prevalence, recurrence rates, and widespread antibiotic use.
The patient pool for uncomplicated UTIs is expanding due to an aging global…
Non-Muscle Invasive Bladder Cancer (NMIBC) Patient Pool Analysis Market Massive …
Introduction
Bladder cancer is one of the most common cancers worldwide, and non-muscle invasive bladder cancer (NMIBC) accounts for nearly 70-75% of all newly diagnosed cases. NMIBC is characterized by tumors confined to the mucosa or submucosa, making it less aggressive than muscle-invasive bladder cancer (MIBC). However, recurrence rates remain high, and progression to advanced stages is a significant concern.
The NMIBC patient pool is expanding globally due to an aging population,…
Metastatic Triple-Negative Breast Cancer (mTNBC) Patient Pool Analysis Market Ou …
Introduction
Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, accounting for 10-15% of all cases. TNBC lacks the three common receptors (estrogen, progesterone, and HER2) that drive other breast cancer subtypes, making it particularly difficult to treat. Standard endocrine or HER2-targeted therapies are ineffective, leaving chemotherapy, immunotherapy, and emerging targeted agents as the main treatment options.
When TNBC progresses to the metastatic stage (mTNBC), prognosis is…
Pediatric Relapsed and Refractory Neuroblastoma Market is expected to reach USD …
Neuroblastoma is one of the most common pediatric solid tumors, primarily affecting children under the age of five. While frontline therapies such as surgery, chemotherapy, radiation, and stem cell transplantation have improved survival in standard-risk patients, the prognosis for relapsed and refractory neuroblastoma remains poor. Children whose disease returns after initial treatment or who fail to respond to frontline therapies face limited therapeutic options and a high risk of mortality.
Download…
More Releases for TTF
Recurrent Malignant Glioma Market Expected to Hit USD 4.0 Billion by 2034
Gliomas are the most common malignant brain tumors, arising from glial cells in the central nervous system. While initial treatment usually involves surgery, radiotherapy, and chemotherapy, recurrence is frequent, and outcomes remain poor. Recurrent malignant gliomas (rMG), including glioblastomas and anaplastic astrocytomas, represent one of the most challenging areas in oncology, with limited treatment options and median survival often less than a year.
Download Full PDF Sample Copy of Market Report…
TTF Mumbai 2025 Wraps Up on a High Note, Rekindling Travel Trade Momentum in the …
Mumbai, 19th August - The much-anticipated, exclusively B2B TTF Mumbai 2025 concluded today, marking a strong return of India's leading travel trade show to the country's financial capital. Held from 11 to 13 August at the Jio World Convention Centre (JWCC), the event brought together over 9,000 travel trade professionals and 500+ exhibitors, reaffirming Mumbai's role as a vital hub in India's travel ecosystem. With the Diwali travel season approaching,…
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
High-Grade Glioma Market is expected to reach USD 9.92 billion by 2034
High-grade gliomas (HGGs) are aggressive brain tumors classified as WHO grade III (anaplastic astrocytoma, anaplastic oligodendroglioma) and grade IV (glioblastoma multiforme). They represent some of the most challenging cancers to treat due to their rapid growth, infiltrative nature, and high recurrence rates. Standard-of-care typically involves surgery, radiation, and chemotherapy, but median survival remains limited, especially for glioblastoma patients.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70861
The next decade will…
Glioblastoma Multiforme Market to Reach USD 6.91 Billion by 2034
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adults, accounting for nearly 50% of malignant brain tumors. Despite advances in surgery, radiotherapy, and chemotherapy, median survival remains just 12-18 months due to tumor heterogeneity, rapid progression, and high recurrence rates.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70857
The next decade is expected to see significant changes in GBM treatment strategies, with novel…
Drone Motors Market 2019 Future Technological Advancement and Phenomenal Growth …
Drone Motors Market is a detailed research study that provides answers and pertinent questions with respect to the emerging trends and growth opportunities in this industry. It helps identify each of the prominent barriers to growth, apart from identifying the trends within various application segments of the Global market for Drone Motors. Collecting historical and recent data from various authentic resources and depending on all the factors and trends, the…
